As of March 20, 2023, around 391 doses of COVID-19 vaccines per 100 people in Cuba had been administered, one of the highest COVID-19 vaccine dose rates of any country worldwide. This statistic shows the rate of COVID-19 vaccine doses administered worldwide as of March 20, 2023, by country or territory.

As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

As of March 15, 2023, Seychelles was the African country with the highest coronavirus (COVID-19) vaccination rate, with around 205 doses administered per 100 individuals. Mauritius and Rwanda followed with 201 and 190 doses per 100 people, respectively. Ranking fourth, Morocco had a vaccination rate of approximately 148 doses per 100 people, registering the third-highest number of inoculations after Egypt and Nigeria. In South Africa, the most affected country on the continent, the vaccination rate instead reached around 64 per 100 population.

How did Africa obtain the vaccines?

Vaccines in Africa were obtained in different ways. African nations both purchased new doses and received them from other countries. At the beginning of the vaccination campaigns, donations came from all over the world, such as China, the United Arab Emirates, India, and Russia. The United Nations-led COVAX initiative provided Oxford/AstraZeneca and Pfizer/BioNTech doses to several African countries. Within this program, the continent received nearly 270 million doses as of January 2022. Moreover, the vaccination campaign has also been an occasion for intra-African solidarity. Senegal has, for instance, donated vaccines to the Gambia, while in January 2021, Algeria announced that it would have shared its supply with Tunisia.

COVID-19 impact on the African economy

The spread of COVID-19 negatively affected socio-economic growth in Africa, with the continent’s Gross Domestic Product (GDP) contracting significantly in 2020. Specifically, Southern Africa experienced the sharpest decline, at minus six percent, followed by North Africa at minus 1.7 percent. Most of Africa’s key economic sectors were hit by the pandemic. The drop in global oil prices led to a crisis in the oil and gas sector. Nigeria, the continent’s leading oil-exporting country, witnessed a considerable decrease in crude oil trade in 2020. Moreover, the shrinking number of international tourist arrivals determined a loss of over 12 million jobs in Africa’s travel and tourism sector. Society has also been substantially affected by COVID-19 on the poorest continent in the world, and the number of people living in extreme poverty was estimated to increase by around 30 million in 2020.

The average for 2022 based on 187 countries was 84 percent. The highest value was in Antigua and Barbuda: 99 percent and the lowest value was in North Korea: 0 percent. The indicator is available from 1980 to 2022. Below is a chart for all countries where data are available.

By August 2024, Cuba had administered the largest number of vaccines against COVID-19 per 100 inhabitants in the Latin American region, followed by Chile and Peru. According to recent estimates, the Caribbean country applied around 410 doses per 100 population, accounting for one of the largest vaccination rates observed not only in the Latin American region, but worldwide. In comparison, Haiti registered the lowest vaccination rate within the region, with only 5.87 doses administered per 100 inhabitants. Booster shots started To reinforce the immune protection against the fast spread of the SARS-CoV-2, governments began to introduce booster shots in their immunization programs aiming at strengthening people’s immune response against new contagious COVID-19 variants. In Latin America, Cuba was leading on booster shots relative to its population among a selection of countries, with around 88 percent of the population receiving the extra dose. In comparison, these numbers are higher than those for the European Union and the United States. Pharmaceutical research continues As Omicron becomes more prominent worldwide, and recombinant variants emerge, research efforts to prevent and control the disease continue to progress. As of June 2022, there were around 2,700 clinical trials to treat COVID-19 and 1,752 COVID-19 vaccines trials in clinical development. Other studies were focused on mild, moderate and severe COVID-19, complication support, and post-COVID symptoms, among others.For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

About this Dataset

The data contains the following information:

Country- this is the country for which the vaccination information is provided; Country ISO Code - ISO code for the country; Date - date for the data entry; for some of the dates we have only the daily vaccinations, for others, only the (cumulative) total; Total number of vaccinations - this is the absolute number of total immunizations in the country; Total number of people vaccinated - a person, depending on the immunization scheme, will receive one or more (typically 2) vaccines; at a certain moment, the number of vaccination might be larger than the number of people; Total number of people fully vaccinated - this is the number of people that received the entire set of immunization according to the immunization scheme (typically 2); at a certain moment in time, there might be a certain number of people that received one vaccine and another number (smaller) of people that received all vaccines in the scheme; Daily vaccinations (raw) - for a certain data entry, the number of vaccination for that date/country; Daily vaccinations - for a certain data entry, the number of vaccination for that date/country; Total vaccinations per hundred - ratio (in percent) between vaccination number and total population up to the date in the country; Total number of people vaccinated per hundred - ratio (in percent) between population immunized and total population up to the date in the country; Total number of people fully vaccinated per hundred - ratio (in percent) between population fully immunized and total population up to the date in the country; Number of vaccinations per day - number of daily vaccination for that day and country; Daily vaccinations per million - ratio (in ppm) between vaccination number and total population for the current date in the country; Vaccines used in the country - total number of vaccines used in the country (up to date); Source name - source of the information (national authority, international organization, local organization etc.); Source website - website of the source of information;

Tasks: Track the progress of COVID-19 vaccination What vaccines are used and in which countries? What country is vaccinated more people? What country is vaccinated a larger percent from its population?

This data is valuble in relation to the health, financial, and engineering sectors.

Category

Health & Medicine

Keywords

Health,Medicine,covid-19,dataset,progress

Row Count

5824

Price

$120.00

As of December 23, 2022, around 80 percent of the population of the United States had been given at least one dose of a COVID-19 vaccination. This statistic shows the percentage of population in select countries and territories worldwide that had received a COVID-19 vaccination as of December 23, 2022.

The average for 2022 based on 187 countries was 85 percent. The highest value was in Antigua and Barbuda: 99 percent and the lowest value was in North Korea: 0 percent. The indicator is available from 1980 to 2022. Below is a chart for all countries where data are available.

BackgroundThe COVID-19 pandemic has disrupted routine childhood vaccinations worldwide with low- and middle-income countries (LMICs) most affected. This study aims to quantify levels of disruption to routine vaccinations in LMICs.MethodsA systematic review (PROSPERO CRD42021286386) was conducted of MEDLINE, Embase, Global Health, CINAHL, Scopus and MedRxiv, on the 11th of February 2022. Primary research studies published from January 2020 onwards were included if they reported levels of routine pediatrics vaccinations before and after March 2020. Study appraisal was performed using NHLBI tool for cross-sectional studies. Levels of disruption were summarized using medians and interquartile ranges.ResultsA total of 39 cross-sectional studies were identified. These showed an overall relative median decline of −10.8% [interquartile range (IQR) −27.6%, −1.4%] across all vaccines. Upper-middle-income countries (upper-MICs) (−14.3%; IQR −24.3%, −2.4%) and lower-MICs (−18.0%; IQR −48.6%, −4.1%) showed greater declines than low-income countries (−3.1%; IQR −12.8%, 2.9%), as did vaccines administered at birth (−11.8%; IQR −27.7%, −3.5%) compared to those given after birth (−8.0%; IQR −28.6%, −0.4%). Declines during the first 3 months of the pandemic (−8.1%; IQR −35.1%, −1.4%) were greater than during the remainder of 2020 (−3.9%; IQR −13.0%, 11.4%) compared to baseline.ConclusionThere has been a decline in routine pediatric vaccination, greatest in MICs and for vaccines administered at birth. Nations must prioritize catch-up programs alongside public health messaging to encourage vaccine uptake.Systematic review registrationIdentifier: CRD42021286386.

CDC COVID-19 Vaccine Tracker

Cumulative and Daily Counts of COVID-19 Vaccine Doses in the United States

By Nicky Forster [source]

About this dataset

The dataset contains data points such as the cumulative count of people who have received at least one dose of the vaccine, new doses administered on a specific date, cumulative count of doses distributed in the country, percentage of population that has completed the full vaccine series, cumulative count of Pfizer and Moderna vaccine doses administered in each state, seven-day rolling averages for new doses administered and distributed, among others.

It also provides insights into the vaccination status at both national and state levels. The dataset includes information on the percentage of population that has received at least one dose of the vaccine, percentage of population that has completed the full vaccine series, cumulative counts per 100k population for both distributed and administered doses.

Additionally, it presents data specific to each state, including their abbreviation and name. It outlines details such as cumulative counts per 100k population for both distributed and administered doses in each state. Furthermore, it indicates if there were instances where corrections resulted in single-day negative counts.

The dataset is compiled from daily snapshots obtained from CDC's COVID Data Tracker. Please note that there may be reporting delays by healthcare providers up to 72 hours after administering a dose.

This comprehensive dataset serves various purposes including tracking vaccination progress over time across different locations within the United States. It can be used by researchers, policymakers or anyone interested in analyzing trends related to COVID-19 vaccination efforts at both national and state levels

How to use the dataset

• Familiarize Yourself with the Columns: Take a look at the available columns in this dataset to understand what information is included. These columns provide details such as state abbreviations, state names, dates of data snapshots, cumulative counts of doses distributed and administered, people who have received at least one dose or completed the vaccine series, percentages of population coverage, manufacturer-specific data, and seven-day rolling averages.

• Explore Cumulative Counts: The dataset includes cumulative counts that show the total number of doses distributed or administered over time. You can analyze these numbers to track trends in vaccination progress in different states or regions.

• Analyze Daily Counts: The dataset also provides daily counts of new vaccine doses distributed and administered on specific dates. By examining these numbers, you can gain insights into vaccination rates on a day-to-day basis.

• Study Population Coverage Metrics: Metrics such as pct_population_received_at_least_one_dose and pct_population_series_complete give you an understanding of how much of each state's population has received at least one dose or completed their vaccine series respectively.

• Utilize Manufacturer Data: The columns related to Pfizer and Moderna provide information about the number of doses administered for each manufacturer separately. By analyzing this data, you can compare vaccination rates between different vaccines.

• Consider Rolling Averages: The seven-day rolling average columns allow you to smooth out fluctuations in daily counts by calculating an average over a week's time window. This can help identify long-term trends more accurately.

• Compare States: You can compare vaccination progress between different states by filtering the dataset based on state names or abbreviations. This way, you can observe variations in distribution and administration rates among different regions.

• Visualize the Data: Creating charts and graphs will help you visualize the data more effectively. Plotting trends over time or comparing different metrics for various states can provide powerful visual representations of vaccination progress.

• Stay Informed: Keep in mind that this dataset is continuously updated as new data becomes available. Make sure to check for any updates or refreshed datasets to obtain the most recent information on COVID-19 vaccine distributions and administrations

Research Ideas

• Vaccination Analysis: This dataset can be used to analyze the progress of COVID-19 vaccinations in the United States. By examining the cumulative counts of doses distributed and administered, as well as the number of people who have received at least one dose or completed the vaccine series, researchers and policymakers can assess how effectively vaccines are being rolled out and monitor...

IntroductionIn relatively wealthy countries, substantial between-country variability in COVID-19 vaccination coverage occurred. We aimed to identify influential national-level determinants of COVID-19 vaccine uptake at different COVID-19 pandemic stages in such countries.MethodsWe considered over 50 macro-level demographic, healthcare resource, disease burden, political, socio-economic, labor, cultural, life-style indicators as explanatory factors and coverage with at least one dose by June 2021, completed initial vaccination protocols by December 2021, and booster doses by June 2022 as outcomes. Overall, we included 61 European or Organisation for Economic Co-operation and Development (OECD) countries. We performed 100 multiple imputations correcting for missing data and partial least squares regression for each imputed dataset. Regression estimates for the original covariates were pooled over the 100 results obtained for each outcome. Specific analyses focusing only on European Union (EU) or OECD countries were also conducted.ResultsHigher stringency of countermeasures, and proportionately more older adults, female and urban area residents, were each strongly and consistently associated with higher vaccination rates. Surprisingly, socio-economic indicators such as gross domestic product (GDP), democracy, and education had limited explanatory power. Overall and in the OECD, greater perceived corruption related strongly to lower vaccine uptake. In the OECD, social media played a noticeable positive role. In the EU, right-wing government ideology exhibited a consistently negative association, while cultural differences had strong overall influence.ConclusionRelationships between country-level factors and COVID-19 vaccination uptake depended on immunization stage and country reference group. Important determinants include stringency, population age, gender and urbanization, corruption, government ideology and cultural context.

This dataset reports the daily reported number of the 7-day moving average rates of Deaths involving COVID-19 by vaccination status and by age group. Learn how the Government of Ontario is helping to keep Ontarians safe during the 2019 Novel Coronavirus outbreak. Effective November 14, 2024 this page will no longer be updated. Information about COVID-19 and other respiratory viruses is available on Public Health Ontario’s interactive respiratory virus tool: https://www.publichealthontario.ca/en/Data-and-Analysis/Infectious-Disease/Respiratory-Virus-Tool Data includes: * Date on which the death occurred * Age group * 7-day moving average of the last seven days of the death rate per 100,000 for those not fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those vaccinated with at least one booster ##Additional notes As of June 16, all COVID-19 datasets will be updated weekly on Thursdays by 2pm. As of January 12, 2024, data from the date of January 1, 2024 onwards reflect updated population estimates. This update specifically impacts data for the 'not fully vaccinated' category. On November 30, 2023 the count of COVID-19 deaths was updated to include missing historical deaths from January 15, 2020 to March 31, 2023. CCM is a dynamic disease reporting system which allows ongoing update to data previously entered. As a result, data extracted from CCM represents a snapshot at the time of extraction and may differ from previous or subsequent results. Public Health Units continually clean up COVID-19 data, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes and current totals being different from previously reported cases and deaths. Observed trends over time should be interpreted with caution for the most recent period due to reporting and/or data entry lags. The data does not include vaccination data for people who did not provide consent for vaccination records to be entered into the provincial COVaxON system. This includes individual records as well as records from some Indigenous communities where those communities have not consented to including vaccination information in COVaxON. “Not fully vaccinated” category includes people with no vaccine and one dose of double-dose vaccine. “People with one dose of double-dose vaccine” category has a small and constantly changing number. The combination will stabilize the results. Spikes, negative numbers and other data anomalies: Due to ongoing data entry and data quality assurance activities in Case and Contact Management system (CCM) file, Public Health Units continually clean up COVID-19, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes, negative numbers and current totals being different from previously reported case and death counts. Public Health Units report cause of death in the CCM based on information available to them at the time of reporting and in accordance with definitions provided by Public Health Ontario. The medical certificate of death is the official record and the cause of death could be different. Deaths are defined per the outcome field in CCM marked as “Fatal”. Deaths in COVID-19 cases identified as unrelated to COVID-19 are not included in the Deaths involving COVID-19 reported. Rates for the most recent days are subject to reporting lags All data reflects totals from 8 p.m. the previous day. This dataset is subject to change.

Travelers Vaccination Market Outlook

The global travelers vaccination market size was valued at USD 7.8 billion in 2023 and is expected to reach USD 14.9 billion by 2032, growing at a CAGR of 7.2% during the forecast period. One of the primary growth factors driving this market is the increasing awareness among travelers about the health risks associated with international travel and the preventive measures that can be taken to mitigate these risks. The growing incidences of infectious diseases in various parts of the world have led to a rise in demand for travel-specific vaccines. Additionally, government initiatives and international guidelines promoting travel vaccinations contribute significantly to market growth.

The rising number of international travelers is a significant factor propelling the growth of the travelers vaccination market. With globalization and the increase in business and leisure travel, more people are exposed to different health risks that are prevalent in different regions. This has led to an increased emphasis on the need for pre-travel consultations and vaccinations to prevent the spread of infectious diseases. The increased connectivity and ease of travel have also made it imperative for travelers to be well-informed about potential health risks and the necessary vaccinations required to mitigate these risks.

Another key growth factor is the advancements in vaccine development technology. The biopharmaceutical industry has made significant strides in developing vaccines that are more effective and have fewer side effects. Innovations in vaccine delivery methods, such as single-dose vaccines and combination vaccines that protect against multiple diseases, have also made it more convenient for travelers to get vaccinated. These advancements have increased the overall acceptance and uptake of travel vaccines, further driving market growth.

Government regulations and international health organizations play a crucial role in the growth of the travelers vaccination market. Many countries have made certain vaccinations mandatory for travelers entering their borders. For instance, the yellow fever vaccine is required for travelers visiting certain countries in Africa and South America. The World Health Organization and the Centers for Disease Control and Prevention also issue guidelines and recommendations for travelers, which include advice on necessary vaccinations. These regulatory requirements and recommendations ensure a steady demand for travel vaccines.

The adult vaccine segment plays a crucial role in the travelers vaccination market, as adults represent a significant portion of international travelers. With the increasing number of adults traveling for business, leisure, and educational purposes, the demand for adult vaccines has seen a notable rise. These vaccines are essential for protecting adult travelers from various infectious diseases that may be prevalent in their destinations. The adult vaccine market is driven by the need for comprehensive protection against diseases such as hepatitis, typhoid, and yellow fever, which are common concerns for travelers. Additionally, the development of new vaccines targeting specific adult health risks further enhances the market's growth potential. As more adults become aware of the importance of vaccinations in safeguarding their health during travel, the adult vaccine segment is expected to witness sustained growth in the coming years.

From a regional perspective, the travelers vaccination market is witnessing significant growth in regions such as Asia Pacific and North America. The Asia Pacific region, in particular, is expected to see a high growth rate due to the increasing number of outbound travelers from countries like China and India. Additionally, the region's susceptibility to various infectious diseases makes travel vaccinations a critical health measure. In North America, the high disposable income and awareness among travelers about health risks contribute to the strong demand for travel vaccines. Europe also holds a substantial market share due to its well-established healthcare infrastructure and the high number of international travelers.

Vaccine Type Analysis

The travelers vaccination market can be segmented by vaccine type, which includes Hepatitis A, Hepatitis B, Typhoid, Yellow Fever, Rabies, Japanese Encephalitis, Meningococcal, and Others. Hepatitis A and B vaccines are among the most commonly administered travel vaccines due to the widespre

Global Export of Vaccines for Human Use Share by Country (US Dollars), 2023 Discover more data with ReportLinker!

As of March 9, 2021, India has secured some 2.2 billion COVID-19 vaccine doses through contracts in total. India chose to purchase vaccines manufactured by AstraZeneca (Oxford), Novavax, and the Russian Gamaleya Institute. However, the overwhelming majority of these doses have yet to be produced and delivered. This statistic shows the size of COVID-19 vaccine contracts based on number of doses secured by countries through contracts with manufacturers. The AstraZeneca/Oxford vaccine is by far the most sought COVID-19 vaccine, especially due to its ability to be stored at normal refrigerator temperatures, while other vaccines need ultra cold storage.

Vaccine Administration Market Outlook

The global vaccine administration market size was estimated at USD 5.2 billion in 2023 and is projected to reach USD 11.4 billion by 2032, with a compound annual growth rate (CAGR) of 9.1%. This impressive growth is driven by several factors, including advancements in vaccine delivery technologies, increased vaccination efforts worldwide, and rising awareness about the importance of immunizations.

One of the primary growth factors for the vaccine administration market is the ongoing global effort to eradicate infectious diseases through widespread immunization programs. Governments and health organizations worldwide have been emphasizing the importance of vaccination, leading to increased vaccine coverage and administration rates. The COVID-19 pandemic has further accentuated the critical role of vaccinations, thereby boosting the market growth. The introduction of novel vaccines and booster doses has necessitated advancements in vaccine delivery systems, contributing to the overall market expansion.

Technological advancements in vaccine administration devices have significantly spurred market growth. Innovations such as needle-free jet injectors, intranasal devices, and improved syringe designs have enhanced the efficiency, safety, and patient compliance of vaccine administration. These advancements reduce the risk of needle-stick injuries, minimize vaccine wastage, and improve the overall vaccination experience. Moreover, the increasing adoption of smart syringes with integrated tracking and safety features aligns with global efforts to ensure vaccine integrity and monitoring.

The collaboration between public and private sectors has been a significant driver in the vaccine administration market. Public health initiatives, partnerships with pharmaceutical companies, and funding from international organizations have bolstered the production, distribution, and administration of vaccines. Financial support for vaccine research and development has accelerated the introduction of new vaccines, creating a robust pipeline for future market growth. Additionally, government policies and reimbursement frameworks have made vaccines more accessible, particularly in low- and middle-income countries, further propelling market expansion.

The regional outlook for vaccine administration is highly promising, with considerable growth anticipated across various geographies. North America, driven by high healthcare expenditure and robust immunization programs, holds a significant market share. The Asia Pacific region is expected to showcase the highest growth rate due to rising healthcare investments, large population base, and increasing awareness regarding vaccine-preventable diseases. Europe also presents substantial growth opportunities, supported by strong government initiatives and advanced healthcare infrastructure. Latin America and the Middle East & Africa, though currently smaller markets, are poised for notable growth due to improving healthcare access and ongoing immunization campaigns.

Product Type Analysis

The vaccine administration market can be segmented by product type into syringes, jet injectors, intranasal devices, and others. Syringes remain the most widely used device for vaccine administration due to their cost-effectiveness, simplicity, and widespread availability. The advancements in syringe technology, such as auto-disable and prefilled syringes, have enhanced safety, reduced contamination risks, and minimized vaccine wastage. The dominance of syringes in the market is further reinforced by their extensive use in routine immunization programs and emergency vaccination drives globally.

Jet injectors represent an innovative leap in the vaccine delivery landscape, offering needle-free administration that improves patient compliance and reduces needle-associated risks. These devices use high-pressure streams to deliver vaccines through the skin, eliminating the need for needles and enhancing the overall vaccination experience. Jet injectors are particularly beneficial in mass immunization settings and for individuals with needle phobia. Their growing popularity is driven by ongoing technological advancements and increasing acceptance among healthcare providers and patients alike.

Intranasal devices have emerged as a promising alternative for vaccine administration, especially for respiratory infections. These devices deliver vaccines directly to the nasal mucosa, eliciting both systemic and mucosal immunity. The ease of administration, coupled with the potential for self-administ

Vaccination against COVID-19 is making progress globally, but vaccine doses remain a rare commodity in many parts of the world. New virus variants mean that updated vaccines become available more slowly. Policymakers have defined criteria to regulate who gets priority access to the vaccination, such as age, health complications, or those who hold system-relevant jobs. But how does the public think about vaccine allocation? To explore those preferences, we surveyed respondents in Brazil, Germany, Italy, Poland, and the United States from September to December of 2020 using ranking and forced-choice tasks. We find that public preferences are consistent with expert guidelines prioritizing health care workers and people with medical preconditions. However, the public also considers those signing up early for vaccination and citizens of the country to be more deserving than later-comers and non-citizens. These results hold across measures, countries, and socio-demographic subgroups.

As of July 2023, the Omicron variant was the most prevalent among selected countries in Latin America. The share of COVID-19 cases corresponding to the Omicron variant amounted to 100 percent of the analyzed sequences of SARS-CoV-2 in Colombia. The variant Omicron (XBB.1.5) accounted for nearly 81 percent of the sequenced cases in the country, while Omicron (XBB.1.9) added up to 14 percent. Similarly, Peru reported over 90 percent of its reviewed sequences corresponding to the variant Omicron (XBB.1.5), while Omicron (XBB) accounted for around 2.4 percent of cases studied.

A regional overview

The Omicron variant of SARS-CoV-2 - the virus causing COVID-19 - was designated as a variant of concern by the World Health Organization in November 2021. Since then, it has been rapidly spreading, causing an unprecedented increase in the number of cases reported worldwide. In Latin America, Brazil had been the most affected country by the disease already before the emergence of the Omicron variant, with nearly 37.4 million cases and around 701,494 confirmed deaths as of May 2, 2023. However, it is Peru that has the largest mortality rate per 100,000 inhabitants due to the SARS-Cov-2 in the region, with roughly 672 deaths per 100,000 people.

Vaccination campaigns in Latin America

As the COVID-19 pandemic continues to cause social and economic harm worldwide, most Latin American and Caribbean countries advance their immunization programs. As of August 14, 2023, Brazil had administered the largest number of vaccines in the region, with over 486.4 million doses. Mexico and Argentina followed, with about 223.1 million and 116 million COVID-19 doses administered, respectively. However, Cuba had the highest vaccination rate not only in the region, but also the world, with around 391 vaccines given per 100 people.

Find the most up-to-date information about the coronavirus pandemic in the world under Statista’s COVID-19 facts and figures site.

Childhood Vaccines Market Outlook

The global childhood vaccines market size was valued at approximately USD 25 billion in 2023 and is projected to reach USD 45 billion by 2032, growing at a CAGR of 6.7% during the forecast period. The primary growth factors driving this market include increased awareness about the importance of immunization, government initiatives, and technological advancements in vaccine development and distribution.

One of the critical growth factors for the childhood vaccines market is the significant increase in awareness about the importance of immunizations in preventing life-threatening diseases. Governments and non-governmental organizations worldwide have launched extensive vaccination programs to ensure higher coverage and to prevent outbreaks of diseases such as measles, mumps, and rubella. The Global Vaccine Action Plan, an initiative by the World Health Organization, aims to extend the benefits of immunization to all people, reinforcing the importance of vaccination programs. Additionally, educational campaigns by healthcare providers and organizations help parents understand the necessity of vaccines, thereby increasing participation rates.

Technological advancements in vaccine development are also significantly contributing to market growth. Modern biotechnology enables the development of more effective and safer vaccines. Advanced techniques such as recombinant DNA technology, synthetic biology, and adjuvant systems have improved the efficacy of vaccines while minimizing side effects. Moreover, the introduction of combination vaccines, which protect against multiple diseases with a single shot, has further enhanced vaccination compliance among parents and caregivers. This technological progress is not only making vaccines more accessible but also ensuring higher immunization rates globally.

The Measle Vaccine has played a pivotal role in reducing the incidence of measles worldwide. With the introduction of the measles vaccine, there has been a dramatic decline in measles-related deaths, especially in regions where the vaccine has been widely administered. The effectiveness of the measles vaccine is attributed to its ability to provide long-lasting immunity, thereby preventing outbreaks and protecting communities. Public health campaigns have emphasized the importance of the measles vaccine in achieving herd immunity, which is crucial for protecting those who cannot be vaccinated due to medical reasons. As a result, the measles vaccine has become a cornerstone of childhood immunization programs globally, contributing significantly to the overall health and well-being of children.

Government policies and funding are another crucial driving factor for the growth of the childhood vaccines market. Various national immunization programs across countries play a vital role in ensuring that vaccines are available and affordable to the population. For instance, the United States has the Vaccines for Children (VFC) program, which provides vaccines at no cost to children who might not otherwise be vaccinated due to financial constraints. Similarly, Gavi, the Vaccine Alliance, supports low-income countries by funding immunization programs and ensuring that children in these regions receive essential vaccines.

Regionally, the childhood vaccines market exhibits varied growth patterns. North America and Europe lead the market due to high healthcare expenditure, robust healthcare infrastructure, and significant government support. However, the Asia Pacific region is expected to witness the fastest growth owing to the large population base, increasing healthcare awareness, and improving healthcare infrastructure. Countries like India and China are making substantial investments in healthcare, including vaccination programs, which is expected to drive market growth in the region. In contrast, regions like Latin America and the Middle East & Africa are showing moderate growth due to economic constraints and limited healthcare infrastructure.

Vaccine Type Analysis

The childhood vaccines market is segmented by vaccine type, which includes live-attenuated vaccines, inactivated vaccines, subunit vaccines, conjugate vaccines, and toxoid vaccines. Each type plays a specific role in immunization programs and has unique characteristics that cater to different healthcare needs. Live-attenuated vaccines, for example, use a weakened form of the virus to stimulate an immune response without causing the disease. These vaccines are highly effective

Current WHO/UNICEF estimates of routine childhood immunization coverage reveal the largest sustained decline in uptake in three decades with pronounced setbacks across Africa. Although the COVID-19 pandemic has induced significant supply and delivery disruptions, the impact of the pandemic on vaccine confidence is less understood. We here examine trends in vaccine confidence across eight sub-Saharan countries between 2020 and 2022 via a total of 17,187 individual interviews, conducted via a multi-stage probability sampling approach and cross-sectional design and evaluated using Bayesian methods. Multilevel regression combined with poststratification weighting using local demographic information yields national and sub-national estimates of vaccine confidence in 2020 and 2022 as well as its socio-demographic associations. We identify declines in perceptions toward the importance of vaccines for children across all eight countries, with mixed trends in perceptions toward vaccine safety and effectiveness. We find that COVID-19 vaccines are perceived to be less important and safe in 2022 than in 2020 in six of the eight countries, with the only increases in COVID-19 vaccine confidence detected in Ivory Coast. There are substantial declines in vaccine confidence in the Democratic Republic of Congo and South Africa, notably in Eastern Cape, KwaZulu-Natal, Limpopo, and Northern Cape (South Africa) and Bandundu, Maniema, Kasaï-Oriental, Kongo-Central, and Sud-Kivu (DRC). While over 60-year-olds in 2022 have higher vaccine confidence in vaccines generally than younger age groups, we do not detect other individual-level socio-demographic associations with vaccine confidence at the sample sizes studied, including sex, age, education, employment status, and religious affiliation. Understanding the role of the COVID-19 pandemic and associated policies on wider vaccine confidence can inform post-COVID vaccination strategies and help rebuild immunization system resilience.